PTGX Q4 2021 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+52.5% YoY

Gross Profit

$8M90.5% margin

Operating Income

-$38M-440.0% margin

Net Income

-$37M-428.3% margin

EPS (Diluted)

$-0.77

QoQ Revenue Growth

-16.2%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$348M

Total Liabilities

$48M

Stockholders' Equity

$300M

Cash & Equivalents

$124M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$6M	+52.5%
Gross Profit	$8M	$6M	+38.0%
Operating Income	-$38M	-$19M	-101.4%
Net Income	-$37M	-$19M	-95.4%

Revenue Segments

License and Collaboration Agreement

$11M100%